This site is intended for healthcare professionals

Go to /sign-in page

You can view 5 more pages before signing in

Go to /pro/cpd-dashboard page

This page is worth 0.05 CPD credits. CPD dashboard

Go to /account/subscription-details page

This page is worth 0.05 CPD credits. Upgrade to Pro

Brolucizumab for treating diabetic macular oedema

Last reviewed dd mmm yyyy. Last edited dd mmm yyyy

Authoring team

Brolucizumab for treating diabetic macular oedema

NICE state that:

  • Brolucizumab is recommended as an option for treating visual impairment due to diabetic macular oedema in adults, only if:
    • the eye has a central retinal thickness of 400 micrometres or more at the start of treatment
    • the company provides brolucizumab according to the commercial arrangement
  • the NICE committee suggest that
    • "..Diabetic macular oedema is usually treated first with aflibercept or ranibizumab, which are already recommended by NICE for treating diabetic macular oedema if the eye has a central retinal thickness of 400 micrometres or more when treatment starts. Brolucizumab is another treatment option that works in a similar way...Evidence from clinical trials shows that brolucizumab is as effective as aflibercept. An indirect comparison of brolucizumab with ranibizumab also suggests similar clinical effectiveness, although this is uncertain."

Brolucizumab

  • is a novel single-chain fragment variable (scFv) antibody that inhibits all isoforms of VEGF-A and prevents binding of this ligand to VEGFR-1 and VEGFR-2
  • has been suggested to have more tissue penetration with 2.2 and 1.7 times higher exposure in neurosensory retina and retinal pigment epithelium (RPE) than bevacizumab and ranibizumab respectively (2)
  • likely also has a more rapid elimination half-life which may partially offset the improved penetration (2)

Reference:


Related pages

Create an account to add page annotations

Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.